Vedolizumab
Ustekinumab
Total Anti-Infliximab
Infliximab
Golimumab
Free Anti-Vedolizumab
Free Anti-Ustekinumab
Free Anti-Infliximab
Free Anti-Golimumab
Free Anti-Etanercept
Free Anti-Adalimumab
EtanerceptAdalimumab
Measuring Adalimumab drug concentrations in patients being treated with Adalimumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Adalimumab allows for reliable measurement of Adalimumab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Adalimumab immediately before the next administration.
Whole blood, Serum, Plasma
10 mins
0.2-50 μg/mL
Quantitative determination of free adalimumab in human whole blood/serum/plasma
Measuring Etanercept drug concentrations in patients being treated with Etanercept for chronic autoimmune conditions.
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Etanercept allows for reliable measurement of Etanercept drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Etanercept immediately before the next administration.
Whole blood, Serum, Plasma
10 mins
0.20~10 μg/mL
Quantitative determination of free etanercept in human whole blood/serum/plasma
Detecting the development of Anti-drug antibodies (ADAs) against Adalimumab in patients being treated with Adalimumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Free Anti-Adalimumab can detect the presence of anti-drug antibodies against Adalimumab, requiring only a small amount of human serum or whole blood, and delivering results in a mere 12 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Whole blood, Serum
12 mins
3-200 AU/mL
Semi-quantitative determination of antibodies against adalimumab in human whole blood/serum
Detecting the development of Anti-drug antibodies (ADAs) against Etanercept in patients being treated with Etanercept for chronic autoimmune conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Free Anti-Etanercept can detect the presence of anti-drug antibodies against Etanercept, requiring only a small amount of human serum or whole blood, and delivering results in a mere 12 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Whole blood, Serum
10 mins
10~100 ng/mL
Quantitative determination of free antibodies against Etanercept in human whole blood/serum
Detecting the development of Anti-drug antibodies (ADAs) against Golimumab in patients being treated with Golimumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Free Anti-Golimumab can detect the presence of anti-drug antibodies against Golimumab, requiring only a small amount of human serum or whole blood, and delivering results in a mere 10 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Whole blood, Serum
10 mins
2-40 ng/mL
Quantitative determination of free antibodies against Golimumab including in human whole blood/serum
Detecting the development of Anti-drug antibodies (ADAs) against Infliximab in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Free Anti-Infliximab can detect the presence of anti-drug antibodies against Infliximab, requiring only a small amount of human serum or whole blood, and delivering results in a mere 12 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Whole blood, Serum
12 mins
4-250 AU/mL
Semi-quantitative determination of free antibodies to infliximab in human whole blood/serum
Detecting the development of Anti-drug antibodies (ADAs) against Ustekinumab in patients being treated with Ustekinumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Free Anti-Ustekinumab can detect the presence of anti-drug antibodies against Ustekinumab, requiring only a small amount of human serum or whole blood, and delivering results in a mere 12 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Whole blood, Serum
12 mins
2.5~100 ng/mL
Quantitative determination of free antibodies to Ustekinumab in human whole blood/serum
Detecting the development of Anti-drug antibodies (ADAs) against Vedolizumab in patients being treated with Vedolizumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Free Anti-Vedolizumab can detect the presence of anti-drug antibodies against Vedolizumab, requiring only a small amount of human serum or whole blood, and delivering results in a mere 10 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Whole blood, Serum
10 mins
10~250 ng/mL
Quantitative determination of free antibodies against Vedolizumab including in human whole blood/serum.
Measuring Golimumab drug concentrations in patients being treated with Golimumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Golimumab allows for reliable measurement of Golimumab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Golimumab immediately before the next administration.
Whole blood, Serum, Plasma
10 mins
0.20-30 μg/mL
Quantitative determination of free Golimumab in human whole blood/serum/plasma
Measuring Infliximab drug concentrations in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Infliximab allows for reliable measurement of Infliximab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Infliximab immediately before the next administration.
plasma, serum, and whole blood
10mins
0.2~50 μg/mL
Quantitative determination of free infliximab in human whole blood/serum/plasma
Detecting the presence of total (free and bound) antibodies against Infliximab in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions.
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Total Anti-Infliximab can detect the presence of anti-drug antibodies against Infliximab, requiring only a small amount of human serum or plasma, and delivering results in 22 minutes. This allows physicians to verify the presence of anti-drug antibodies immediately before the next administration.
Serum, Plasma
22 mins
8-250 AU/mL
Semi-quantitative determination of free and bound antibodies against Infliximab in human serum/plasma
Measuring Ustekinumab drug concentrations in patients being treated with Ustekinumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Ustekinumab allows for reliable measurement of Ustekinumab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Ustekinumab immediately before the next administration.
Whole blood, Serum, and Plasma
10 mins
0.5-20 μg/mL
Quantitative determination of free Ustekinumab in human whole blood/serum/plasma
Measuring Vedolizumab drug concentrations in patients being treated with Vedolizumab for chronic autoimmune and inflammatory conditions
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Vedolizumab allows for reliable measurement of Vedolizumab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Vedolizumab immediately before the next administration.
Whole blood, Serum, and Plasma
10 mins
2~60 μg/mL
Quantitative determination of free Vedolizumab in human whole blood/serum/plasma
Your Trusted Partner in Medical Diagnostics.
Distribution Across Odisha – Easy Online Ordering at Your Fingertips
Stay in touch for the latest updates. No spam, we promise.
Copyright © 2025 Odisha Scientific House. Designed & Developed by Beyond Pixel Studio. admin@beyondpixel.online
Reviews
There are no reviews yet.